Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.
Endometrial cancer
Isolated paraaortic metastasis
Lymph nodes
Stage IIIC
Ultrastaging
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
22
03
2019
revised:
06
05
2019
accepted:
07
05
2019
pubmed:
28
5
2019
medline:
27
8
2019
entrez:
26
5
2019
Statut:
ppublish
Résumé
This study aimed to determine the prevalence of occult pelvic lymph node metastasis in patients with endometrial cancer (EC) with isolated paraaortic dissemination who underwent pelvic and paraaortic lymphadenectomy. From 2004 to 2008, patients undergoing surgery for EC at our institution were prospectively treated according to a validated surgical algorithm relying on intraoperative frozen section. For the current study, we re-reviewed pathologic slides obtained at the time of diagnosis and performed ultrastaging of all negative pelvic lymph nodes to assess the prevalence of occult pelvic lymph node metastasis. Of 466 patients at risk for lymphatic dissemination, 394 (84.5%) underwent both pelvic and paraaortic lymphadenectomy. Of them, 10 (2.5%) had isolated paraaortic metastasis. Pathologic review of hematoxylin-eosin-stained slides identified 1 patient with micrometastasis in 1 of 18 pelvic lymph nodes removed. Ultrastaging of 296 pelvic lymph nodes removed from the 9 other patients (median [range], 32 [20-50] nodes per patient) identified 2 additional cases (1 with micrometastasis and 1 with isolated tumor cells), for a total of 3/10 patients (30%) having occult pelvic dissemination. Ultrastaging and pathologic review of negative pelvic lymph nodes of patients with presumed isolated paraaortic metastasis can identify occult pelvic dissemination and reduce the prevalence of true isolated paraaortic disease. In the era of the sentinel lymph node (SLN) algorithm for EC staging, which incorporates ultrastaging of the SLNs removed, these findings demonstrate that use of the SLN algorithm can further mitigate the concern of missing cases of isolated paraaortic dissemination.
Identifiants
pubmed: 31126637
pii: S0090-8258(19)31234-X
doi: 10.1016/j.ygyno.2019.05.008
pmc: PMC6612056
mid: NIHMS1032959
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
60-64Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Ann Surg Oncol. 2018 Nov;25(12):3692-3698
pubmed: 30116949
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Gynecol Oncol. 2011 Oct;123(1):58-64
pubmed: 21741696
Oncology (Williston Park). 2017 May 15;31(5):390-1, 401
pubmed: 28516437
Int J Clin Oncol. 2013 Apr;18(2):193-9
pubmed: 23412768
Gynecol Oncol. 2014 Jan;132(1):38-43
pubmed: 24120926
J Obstet Gynaecol Res. 2014 Feb;40(2):327-34
pubmed: 24620369
Int J Gynecol Cancer. 2013 Jun;23(5):964-70
pubmed: 23694985
Ann Oncol. 2016 Jan;27(1):16-41
pubmed: 26634381
Int J Gynecol Cancer. 2019 Jan;29(1):60-67
pubmed: 30640685
Gynecol Oncol. 2008 Apr;109(1):11-8
pubmed: 18304622
J Natl Compr Canc Netw. 2014 Feb;12(2):288-97
pubmed: 24586087
Am J Obstet Gynecol. 2017 May;216(5):459-476.e10
pubmed: 27871836
Gynecol Oncol. 2012 Dec;127(3):532-7
pubmed: 22940490
Cancer. 1987 Oct 15;60(8 Suppl):2035-41
pubmed: 3652025
Obstet Gynecol. 2015 Apr;125(4):1006-26
pubmed: 25798986
Gynecol Oncol. 2010 Nov;119(2):291-4
pubmed: 20708226
Gynecol Oncol. 2014 Feb;132(2):275-9
pubmed: 24291694
Gynecol Oncol. 2017 Aug;146(2):234-239
pubmed: 28528918
Lancet Oncol. 2018 Oct;19(10):1394-1403
pubmed: 30143441
Cancer. 1993 Feb 15;71(4 Suppl):1460-3
pubmed: 8431880
Gynecol Oncol. 2009 Nov;115(2):236-8
pubmed: 19666190
Gynecol Oncol. 2014 Aug;134(2):385-92
pubmed: 24905773
Gynecol Oncol. 2004 Mar;92(3):833-8
pubmed: 14984949
Gynecol Oncol. 2012 Oct;127(1):5-10
pubmed: 22771890
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Gynecol Oncol. 2017 Aug;146(2):405-415
pubmed: 28566221
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Gynecol Oncol. 2018 Mar;148(3):480-484
pubmed: 29338923
Gynecol Oncol. 2003 Dec;91(3):518-25
pubmed: 14675670